USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
08 Sep 2022 | 02:45 PM GMT

DTx Evidence Generation: What can we learn from the Pharma and Medical Device Industries?

Anchored by:

Luis Fernandez Luque
Chief Scientific Officer
ADHERA HEALTH

Participants:

Luis Fernandez Luque Chief Scientific OfficerAdhera Health
Luis Fernandez Luque
Chief Scientific OfficerAdhera Health
Myles Furnace Chief Commercial OfficerEolas Medical
Myles Furnace
Chief Commercial OfficerEolas Medical
Adriano Garcez Director, DTx/SaMD Evidence GenerationZS Associates
Adriano Garcez
Director, DTx/SaMD Evidence GenerationZS Associates
Ameya Phadke Senior Director, Non Pharma SolutionsChiesi Group
Ameya Phadke
Senior Director, Non Pharma SolutionsChiesi Group
Anna-Maria Heidinger Head of Digital Innovation HubDaiichi Sankyo Europe
Anna-Maria Heidinger
Head of Digital Innovation HubDaiichi Sankyo Europe
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Emma Carr Co-Founder and Chief Scientific OfficerAmara Therapeutics
Emma Carr
Co-Founder and Chief Scientific OfficerAmara Therapeutics
Kasparas Aleknavicius Medical AdvisorKilo.Health
Kasparas Aleknavicius
Medical AdvisorKilo.Health
Philipp Unruh Digital Product ManagerBayer AG
Philipp Unruh
Digital Product ManagerBayer AG

About this Meeting

The definition of Digital Therapeutics (DTx) is broad,  including many different solutions, making it hard to agree on the evidence generation standards. While DTx are very different from drugs and other medical devices, pharma and medtech companies have years of expertise in generating clinical and health economics evidence. In this meeting, we want to deep dive into what learnings the DTx industry can take from them and how should the standards evolve to capture the nuances of this new type of therapy. Join this meeting to have a peer-to-peer conversation about: 

  • What can the DTx industry learn from pharma and medtech in building the evidence needed to get regulators, payers, and physicians to listen?  
  • In DTx, there is no one way, with different approaches that work for some products but not for others. This can also be true for drugs or other medical devices. How do pharma and medtech companies change their evidence generation approach depending on the product and the geographies? What learnings can we take to the DTx industry?  
  • It is not a secret that DTx and drugs are not the same, hence the standards need to evolve to adapt to these new digital therapies. What other non-traditional evidence is needed for DTx? What should DTx companies do differently from pharma and medtech when generating evidence for their products?  
  • Partnering with pharma and medtech companies to generate the evidence. Is this helpful for DTx companies or does it translate into more obstacles and longer trials?